股价表现与市场数据 - 伯恩斯坦于2026年1月20日为安进设定335美元的目标价 当时股价为330.44美元 隐含约1.38%的潜在上涨空间 [1] - 当前股价为330.06美元 日内小幅下跌0.35美元或-0.11% 日内交易区间为321.71美元至330.83美元 [2] - 过去52周股价波动显著 最高达346.38美元 最低至261.43美元 [2] - 公司市值约为1777.3亿美元 在制药行业占据重要地位 [3] - 当日交易量为971,158股 显示投资者对该股兴趣活跃 [3] 法律诉讼风险 - 安进面临法律挑战 拉斯维加斯的非营利组织Sagebrush Health Services已对公司提起诉讼 [4] - 诉讼指控安进非法终止了向该组织诊所的折扣药品销售 并追回了数百万美元的历史折扣 影响了内华达州超过10,000名患者 [4] - 此法律问题可能影响公司声誉和财务表现 并可能影响股价未来走势及达到伯恩斯坦目标价的能力 [5]

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Janua ...

公司概况与市场地位 - 默克公司是一家全球医疗保健公司，致力于开发和制造广泛的医药产品，以其在肿瘤学、疫苗和传染病等领域的创新研究而闻名 [1] - 公司面临来自辉瑞和强生等其他制药巨头的竞争 [1] 近期股价与市场表现 - 当前股价为108.83美元，当日下跌1.93%，跌幅为2.14美元 [5] - 当日交易区间在108.43美元至110.72美元之间 [5] - 公司市值约为2718.3亿美元 [5] - 当日交易量为1072万股，表明在这些积极进展下投资者兴趣活跃 [5] 机构评级与目标价调整 - Cowen & Co. 维持对默克公司的“持有”评级 [2][6] - TD Cowen 将默克公司的目标价从100美元上调至120美元，显示出对公司未来表现的乐观态度 [2][6] 研发进展与关键产品 - 默克与Moderna合作的癌症疫苗研究取得积极成果，该疫苗旨在治疗黑色素瘤 [3] - 在一项2b期试验中，该疫苗显著降低了患者复发或死亡的风险 [3] - 实验性皮肤癌疫苗与默克的Keytruda联合使用，在一项中期试验中显示出将复发或死亡风险降低49% [4][6] - 该联合疗法的益处持续了五年，突显了其在治疗严重皮肤癌方面的潜在影响 [4][6] - 这一积极成果标志着癌症治疗领域的重大进展，可能为黑色素瘤患者带来新的治疗选择 [3][6]

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

In this articlePFENVOUS President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty ImagesDrug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0.Those are among the themes that dominated conversations last week as drugmakers of all sizes met with investors to map out their plans for 2026 and beyond at the annual JPMorgan Healthcare Conference in San Francisco. After geopolit ...

Key Takeaways OGN received FDA approval extending NEXPLANON's contraceptive use from three years to up to five years.Trial data show no pregnancies in years four and five, showing efficacy across a wide range of BMIs.The approval introduces a new REMS program to certify providers for proper insertion and removal.Organon & Co. (OGN) recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque to up to five ...

AstraZeneca Plc (NASDAQ:AZN) said Tuesday it will voluntarily delist its American Depositary Shares and certain guaranteed debt securities from the Nasdaq as it transitions to a direct stock listing on the New York Stock Exchange (NYSE).The company previously announced that its ordinary shares and the affected debt securities will begin trading on the NYSE following market close on January 30, 2026, with trading expected to start on February 2, 2026. The Nasdaq listings are expected to cease on January 30.T ...

LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush's clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufacturers. Guru Ch ...

Mumbai: Ahmedabad-based Zydus Lifesciences is evaluating acquisition of a majority stake in US-based Ardelyx Inc., with the deal likely to be valued at $2.2–2.5 billion, two people aware of the development told Mint . The proposed transaction would be funded through a ₹5,000-crore equity raise via a qualified institutional placement (QIP) and internal cash accruals, the people said. If concluded, the deal would significantly accelerate Zydus’s push into global innovative medicine, an avenue that is attracti ...